Starting July 1, Medicare will cover obesity drugs for eligible seniors through its new Bridge demonstration program, requiring a $50 monthly copay. This marks a major expansion in access to treatments from Novo Nordisk and Eli Lilly, previously unaffordable for many. However, awareness is low, with 82% of seniors unaware of the change, partly due to limited public advertising before launch. The program requires enrollment and prior authorization, and officials are focusing on preparing providers and pharmacies before broad public outreach to ensure smooth implementation.
GLP-1 weight-loss pills from Novo Nordisk and Eli Lilly are driving high demand among employees, but their high costs are causing many large employers to reduce or reconsider coverage. Although oral pills are as expensive as injectables and less effe...
UBS projects the global market for GLP-1 drugs, used in obesity and diabetes, to reach $130-135 billion by 2030 with about 40 million patients, up from 25 million in 2026. Obesity is the main growth driver, and current low penetration in eligible pat...
Novo Nordisk reported a 4% sales decline in Q1 FY26 excluding a $4.2B accounting reversal, with key drugs Ozempic and Rybelsus dropping significantly. The company also announced major price cuts for Wegovy and Ozempic in 2027 and faced setbacks with ...
